Gavel with drugs The ruling“clears the way for us to begin obtaining discovery from themanufacturers and PBMs so we can shine the light on exactly whathas driven insulin prices sky-high,'' Steve Berman, a plaintiffs'lawyer. (Photo: Shutterstock)

Novo Nordisk A/S and two other insulin makers must face claimsthey gouged diabetes patients through deceptiveprice lists for their life-saving drugs.

U.S. District Judge Brian Martinotti in New Jersey on Fridayallowed a proposed class-action lawsuit filed by 67 diabeticsagainst Novo, Eli Lilly & Co. and the U.S. unit of Frenchdrugmaker Sanofi to proceed on consumer-fraud allegations tied toskyrocketing insulin prices. The judge threwout the plaintiffs' racketeering claims.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Cost-Containment